Survival of lethal poxvirus infection in mice depends on TLR9, and therapeutic vaccination provides protection
about
Innate immune sensing of DNA virusesToll-like receptors: key players in antiviral immunityThe effects of post-exposure smallpox vaccination on clinical disease presentation: addressing the data gaps between historical epidemiology and modern surrogate model dataToll-like receptors in antiviral innate immunityCritical role of perforin-dependent CD8+ T cell immunity for rapid protective vaccination in a murine model for human smallpoxInnate immune sensing of modified vaccinia virus Ankara (MVA) is mediated by TLR2-TLR6, MDA-5 and the NALP3 inflammasomeSequential Activation of Two Pathogen-Sensing Pathways Required for Type I Interferon Expression and Resistance to an Acute DNA Virus InfectionImmune requirements of post-exposure immunization with modified vaccinia Ankara of lethally infected miceCandidate influenza vaccines based on recombinant modified vaccinia virus Ankara.Protective effect of Toll-like receptor 4 in pulmonary vaccinia infectionMousepox in the C57BL/6 strain provides an improved model for evaluating anti-poxvirus therapies.A randomized, double-blind, dose-finding Phase II study to evaluate immunogenicity and safety of the third generation smallpox vaccine candidate IMVAMUNE.Modified vaccinia virus Ankara exerts potent immune modulatory activities in a murine modelToll-like receptor 8-mediated activation of murine plasmacytoid dendritic cells by vaccinia viral DNAIn vitro host range, multiplication and virion forms of recombinant viruses obtained from co-infection in vitro with a vaccinia-vectored influenza vaccine and a naturally occurring cowpox virus isolate.Targeting the TLR9-MyD88 pathway in the regulation of adaptive immune responses.Impact of distinct poxvirus infections on the specificities and functionalities of CD4+ T cell responsesToll-like receptor agonists: are they good adjuvants?Introduction of the six major genomic deletions of modified vaccinia virus Ankara (MVA) into the parental vaccinia virus is not sufficient to reproduce an MVA-like phenotype in cell culture and in mice.Rapid expansion of CD8+ T cells in wild-type and type I interferon receptor-deficient mice correlates with protection after low-dose emergency immunization with modified vaccinia virus Ankara.Innate immune response of human plasmacytoid dendritic cells to poxvirus infection is subverted by vaccinia E3 via its Z-DNA/RNA binding domainTLR3 and TLR9 agonists improve postexposure vaccination efficacy of live smallpox vaccines.Therapeutic Vaccines and Antibodies for Treatment of Orthopoxvirus Infections.Immunization with a recombinant vaccinia virus that encodes nonstructural proteins of the hepatitis C virus suppresses viral protein levels in mouse liverTcVac3 induced control of Trypanosoma cruzi infection and chronic myocarditis in mice.N1L is an ectromelia virus virulence factor and essential for in vivo spread upon respiratory infection.IMVAMUNE: modified vaccinia Ankara strain as an attenuated smallpox vaccine.Novel drugs targeting Toll-like receptors for antiviral therapy.Deletion of major nonessential genomic regions in the vaccinia virus Lister strain enhances attenuation without altering vaccine efficacy in mice.Identification of Toll-like receptor 9 as parapoxvirus ovis-sensing receptor in plasmacytoid dendritic cellsMyxoma virus induces type I interferon production in murine plasmacytoid dendritic cells via a TLR9/MyD88-, IRF5/IRF7-, and IFNAR-dependent pathway.Poxvirus Protein MC132 from Molluscum Contagiosum Virus Inhibits NF-B Activation by Targeting p65 for Degradation.A Multicenter, Open-Label, Controlled Phase II Study to Evaluate Safety and Immunogenicity of MVA Smallpox Vaccine (IMVAMUNE) in 18-40 Year Old Subjects with Diagnosed Atopic Dermatitis.A Randomized, Double-Blind, Placebo-Controlled Phase II Trial Investigating the Safety and Immunogenicity of Modified Vaccinia Ankara Smallpox Vaccine (MVA-BN®) in 56-80-Year-Old Subjects.A single cidofovir treatment rescues animals at progressive stages of lethal orthopoxvirus disease.Harnessing the unique local immunostimulatory properties of modified vaccinia Ankara (MVA) virus to generate superior tumor-specific immune responses and antitumor activity in a diversified prime and boost vaccine regimenSafety, immunogenicity, and surrogate markers of clinical efficacy for modified vaccinia Ankara as a smallpox vaccine in HIV-infected subjects.Learning from the messengers: innate sensing of viruses and cytokine regulation of immunity - clues for treatments and vaccines.Therapeutic vaccination to treat chronic infectious diseases: current clinical developments using MVA-based vaccines.Cowpox virus inhibits human dendritic cell immune function by nonlethal, nonproductive infection.
P2860
Q24626598-AF65F871-FE8D-4DAE-8378-57C4F5C00369Q26865983-EF9BB65B-884A-4570-9432-6ACECECB5B64Q26996686-714B0F18-C799-4027-A138-B89D7E7A8E92Q27011462-801D19EE-CAC2-41DA-BAF5-F504CBA3A25DQ27346933-9FFF7495-2C8A-4390-8C92-7CC07C27CD51Q28389050-675BE1D7-A1FB-4A6A-BA3A-76AD752EBA9BQ28603889-0BA4A606-CBE1-46B9-B541-CA34492B1669Q28748570-0A33B249-F46A-4700-AF95-1ED65EA714F3Q30375979-03FDBE9F-738D-4AE8-9B82-52032C7A42A4Q33370547-01C5542B-C557-4094-8D9B-712D0BBA9D09Q33570349-DEF7C7E6-6872-45D6-8DD4-B6912790F5BAQ33624420-C668D393-9673-4CAA-B6BE-5F5D2D9EF7CEQ33632203-D9104A07-3BD0-4386-BE30-A287405C09E7Q33778828-F6446AD3-EA17-429B-9FB8-7F3035926E0EQ34017475-84FAB572-101B-4FA9-BCB7-831CDDA09A7CQ34048648-8FCD9B80-EC72-4379-9EE9-76F060731F53Q34059488-7452925A-39D6-4192-A1D2-E253A827AA93Q34067537-DBCB5DE4-7AAD-4548-A7B2-25D862E04B5EQ34120696-CCC005BF-9058-4C37-B6C9-C91070D6BAFDQ34262138-2C0364E0-4ED5-46F7-9222-B62868E9BB7CQ34273718-5A703635-FED5-435B-8CDB-AE228C2A89B7Q34414790-CDD30901-FAE4-48E7-9F56-F2C091CAA0DEQ34447009-9E709D81-3003-4620-86FB-0D54ABA94A2BQ34532114-8D238842-52C6-4CA4-A573-CAE33545FC4BQ34651261-E98C8F5C-44A7-4FC2-BCAD-A17140379F62Q34742613-1E93FC1F-1EF9-4DD6-AE0F-2CD23B2586D3Q34907430-D92E8130-4626-4BED-891E-39260301DB64Q34999938-319A254C-B97E-473B-8142-A4A2EBFD9109Q35076706-992832BE-B243-4BCD-83AB-0E9C5DC69BD2Q35235154-A28A370B-5DE4-4043-8061-6AD4DC93FAD8Q35274869-A5CA72C9-4C07-4FE1-956F-3968B38715A5Q35652144-0262BE48-6833-4C1B-8FC9-0C004CA007AAQ35800226-13FCC9C5-6C4C-4348-8BF9-CA3357581B2DQ36057928-635CB6C5-D9EC-4390-AA98-82CE4AE142E6Q36130201-63344BC0-763A-4BEC-8E1B-E7FA346D97EFQ36456190-1855F4DF-B201-4DA0-9D2E-6249014D06A4Q36727280-0F8E735D-4DC1-4640-83A5-8B6175E581A3Q36807121-3A3CB0AA-6D5D-478D-A5B4-589E601DE136Q36849770-0121A26D-0E07-45BE-A344-2DD8B2267600Q36961137-8E09ED51-D1F3-4B08-BD47-F2974CC0588D
P2860
Survival of lethal poxvirus infection in mice depends on TLR9, and therapeutic vaccination provides protection
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Survival of lethal poxvirus in ...... accination provides protection
@ast
Survival of lethal poxvirus in ...... accination provides protection
@en
type
label
Survival of lethal poxvirus in ...... accination provides protection
@ast
Survival of lethal poxvirus in ...... accination provides protection
@en
prefLabel
Survival of lethal poxvirus in ...... accination provides protection
@ast
Survival of lethal poxvirus in ...... accination provides protection
@en
P2093
P2860
P356
P1476
Survival of lethal poxvirus in ...... accination provides protection
@en
P2093
Christofer Samuelsson
Henning Lauterbach
Hermann Wagner
Hubertus Hochrein
Jürgen Hausmann
Mark Suter
Meredith O'Keeffe
Michaela Schmidt
Paul Chaplin
Shizuo Akira
P2860
P304
P356
10.1172/JCI33940
P407
P577
2008-05-01T00:00:00Z